Literature DB >> 12850669

Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice.

Lu Wang1, Wei-Zhong Wu, Hui-Chuan Sun, Xiao-Feng Wu, Lun-Xiu Qin, Yin-Kun Liu, Kang-Da Liu, Zhao-You Tang.   

Abstract

The aim of this study was to examine the mechanism of interferon alpha (IFN-alpha) on inhibition of metastasis and recurrence of hepatocellular carcinoma (HCC). Nude mice bearing human HCC xenografts with high metastatic potential (LCI-D20) underwent curative resection of tumors on postimplant day 11. IFN-alpha was begun the next day at different dosages given subcutaneously for 35 consecutive days; normal saline solution was injected into the control mice. The mice were killed 48 hours after the final treatment, and the parameters were evaluated. The HCC intrahepatic recurrence rate, the size of the recurrent lesions, the rate of lung metastasis, the serum vascular endothelial growth factor level, and the microvessel density (immunohistochemistry) were as follows: 100%, 2136+/-794 mm(3)(mean+/-standard deviation), 100%, 265.7+/-154.7 pg/ml, and 144+/-37/HP, respectively, in the control mice, whereas these same values were 62.5%, 89+/-45 mm(3), 12.5%, 53.3+/-9.9 pg/ml, and 86+/-25/HP, respectively, in the IFN-alpha 1.5 x 10(7)U/kg treatment group (P<0.05) and 26.7%, 46+/-21 mm(3), 0%, 65.2+/-17.9 pg/ml, and 39+/-14/HP in the IFN-alpha 3 x 10(7)U/kg treatment group, respectively (P<0.05). However, a significant difference was not found in the serum levels of basic fibroblast growth factor among the control and IFN-alpha treatment groups. IFN-alpha inhibits metastasis and recurrence of human HCC after curative resection in nude mice mediated by antiangiogenesis through downregulating expression of vascular endothelial growth factor but not basic fibroblast growth factor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12850669     DOI: 10.1016/s1091-255x(03)00072-6

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  40 in total

1.  The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma.

Authors:  O N El-Assal; A Yamanoi; T Ono; H Kohno; N Nagasue
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

Review 2.  Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.

Authors:  D Hanahan; J Folkman
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

3.  Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b.

Authors:  P B Vermeulen; L Y Dirix; M Martin; J Lemmens; A T Van Oosterom
Journal:  J Natl Cancer Inst       Date:  1997-09-03       Impact factor: 13.506

4.  Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus.

Authors:  J Zhou; Z Y Tang; J Fan; Z Q Wu; X M Li; Y K Liu; F Liu; H C Sun; S L Ye
Journal:  J Cancer Res Clin Oncol       Date:  2000-01       Impact factor: 4.553

5.  Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma.

Authors:  X M Li; Z Y Tang; L X Qin; J Zhou; H C Sun
Journal:  J Exp Clin Cancer Res       Date:  1999-12

6.  Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study.

Authors:  Ronnie Tung-Ping Poon; Irene Oi-Lin Ng; Cecilia Lau; Wun-Ching Yu; Zhen-Fan Yang; Sheung-Tat Fan; John Wong
Journal:  J Clin Oncol       Date:  2002-04-01       Impact factor: 44.544

7.  Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment.

Authors:  S Ulisse; P Gionchetti; S D'Alò; F P Russo; I Pesce; G Ricci; F Rizzello; U Helwig; M G Cifone; M Campieri; C De Simone
Journal:  Am J Gastroenterol       Date:  2001-09       Impact factor: 10.864

8.  Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: critical role of STAT-1alpha.

Authors:  Z Ma; H Qin; E N Benveniste
Journal:  J Immunol       Date:  2001-11-01       Impact factor: 5.422

9.  Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma.

Authors:  R T Poon; I O Ng; C Lau; W C Yu; S T Fan; J Wong
Journal:  Am J Surg       Date:  2001-09       Impact factor: 2.565

10.  Geometric resistance and microvascular network architecture of human colorectal carcinoma.

Authors:  J R Less; M C Posner; T C Skalak; N Wolmark; R K Jain
Journal:  Microcirculation       Date:  1997-03       Impact factor: 2.628

View more
  22 in total

1.  Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.

Authors:  Jian-Hua Ma; Emilia Patrut; Jan Schmidt; Hanns-Peter Knaebel; Markus W Büchler; Angela Märten
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

Review 2.  Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma.

Authors:  Shinji Tanaka; Shigeki Arii
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

3.  Long-term interferon-α treatment suppresses tumor growth but promotes metastasis capacity in hepatocellular carcinoma.

Authors:  Peng-Yuan Zhuang; Ju-Bo Zhang; Wei Zhang; Xiao-Dong Zhu; Ying Liang; Hua-Xiang Xu; Yu-Quan Xiong; Ling-Qun Kong; Lu Wang; Wei-Zhong Wu; Zhao-You Tang; Lun-Xiu Qin; Hui-Chuan Sun
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-06       Impact factor: 4.553

Review 4.  Viral hepatitis and hepatocellular carcinoma: etiology and management.

Authors:  Philippe J Zamor; Andrew S deLemos; Mark W Russo
Journal:  J Gastrointest Oncol       Date:  2017-04

5.  High hepatitis B viral load predicts recurrence of small hepatocellular carcinoma after curative resection.

Authors:  Li-Shuai Qu; Fei Jin; Xiao-Wu Huang; Xi-Zhong Shen
Journal:  J Gastrointest Surg       Date:  2010-04-27       Impact factor: 3.452

6.  Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: A meta-analysis with comparison of different types of hepatitis.

Authors:  Wei Zhang; Tian-Qiang Song; Ti Zhang; Qiang Wu; DA-Lu Kong; Qiang Li; Hui-Chuan Sun
Journal:  Mol Clin Oncol       Date:  2014-08-12

7.  Inhibitory effect of interferon-alpha-2b on expression of cyclooxygenase-2 and vascular endothelial growth factor in human hepatocellular carcinoma inoculated in nude mice.

Authors:  Bin Cao; Xiao-Ping Chen; Peng Zhu; Lei Ding; Jian Guan; Zuo-Liang Shi
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

8.  Herbal compound "Songyou Yin" reinforced the ability of interferon-alfa to inhibit the enhanced metastatic potential induced by palliative resection of hepatocellular carcinoma in nude mice.

Authors:  Xiu-Yan Huang; Zi-Li Huang; Lu Wang; Yong-Hua Xu; Xin-Yu Huang; Kai-Xing Ai; Qi Zheng; Zhao-You Tang
Journal:  BMC Cancer       Date:  2010-10-25       Impact factor: 4.430

9.  Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial.

Authors:  Hui-Chuan Sun; Zhao-You Tang; Lu Wang; Lun-Xiu Qin; Zeng-Chen Ma; Qin-Hai Ye; Bo-Heng Zhang; Yong-Bin Qian; Zhi-Quan Wu; Jia Fan; Xin-Da Zhou; Jian Zhou; Shuang-Jian Qiu; Yue-Fang Shen
Journal:  J Cancer Res Clin Oncol       Date:  2006-03-24       Impact factor: 4.553

10.  A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.

Authors:  Chung Mau Lo; Chi Leung Liu; See Ching Chan; Chi Ming Lam; Ronnie T P Poon; Irene O L Ng; Sheung Tat Fan; John Wong
Journal:  Ann Surg       Date:  2007-06       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.